The biological activity of the steroidal oximes was predicted by the PASS (Prediction of Activity Spectra Substances)
computer program.
Antimicrobial, antifungal, anti-inflammatory, and antiatherosclerotic activity was most probable for all oximes
synthesized by us (1–7).
An in vitro experiment with 3,17-dihydroxyiminoandrost-4-ene (6) showed activity against several fungus strains
(Sporobolom salmonicolor, Candida glabrata, Penicillium notatum, Aspergillus terreus, A. niger, A. fumigatus) that was
comparable with that of amphotericin and nystatin.
Also, the predicted anti-inflammatory activity of 3ꢂ-hydroxy-17-hydroximino-5ꢀ-androstane (3) was consistent with
a biological experiment because 3 acted as a selective blocker of the enzyme cyclooxygenase-2. The other oximes (1, 2, 4, 5,
7) exhibited moderate or low activity.
A trial was performed at the Hans Knoll Institute of Natural Compounds and Infectious Biology (Germany). It was
found that a double bond, even moreso conjugated (6), enhanced the antimicrobial activity whereas an OH group on C-3 (3)
increased the anti-inflammatory activity of the steroidal oximes.
IR spectra were recorded in KBr disks on a Thermo Nicolet Avatar-370 spectrometer. PMR spectra were measured in
CDCl on a Bruker AM-400 (400 MHz) spectrometer; melting points, on a Boetius heating stage.
3
The course of reactions and purity of products were monitored by TLC on Silufol UV-254 plates using benzene:acetone,
6:1. Elemental analyses of all compounds agreed with those calculated.
3ꢂ-(4-Methylphenylsulfonyloxy)-5ꢀ-pregnan-20-one (9). A solution of ketone 8 (1 g, 3.1 mmol) in anhydrous Py
(3 mL) at 0–5°C was treated over 1 h with p-toluenesulfonylchloride (2 g, 10.1 mmol). The reaction mixture was stirred for
3 h at 20–25°C, treated with conc. HCl (3 mL), and held at 0–5°C for 5 h. The resulting precipitate was filtered off, washed
–1
with water, and dried. Crystallization from benzene produced 1.2 g (90%) of 9, mp 95–98°C. IR spectrum (ꢃ, cm ): 1740,
1680 (C=O), 1590 (C=C, Ar). PMR spectrum (ꢁ, ppm, J/Hz): 062 (3H, s, 18-CH ), 0.84 (3H, s, 19-CH ), 2.12 (3H, s,
3
3
21-CH ), 2.45 (3H, s, CH -Ar), 7.35 (2H, d, J = 8, H-Ar), 8.24 (2H, d, J = 8, H-Ar).
3
3
5ꢀ-Pregn-2-en-20-one (10). A solution of tosylate 9 (1.4 g, 2.9 mmol) in freshly distilled DMF (15 mL) was treated
with LiBr (1.2 g, 13.6 mmol) over 2 h, refluxed for 2 h, cooled to 20°C, and diluted with water (300 mL). The resulting
crystals were filtered off and washed with water to afford 0.7 g of crude product. Crystallization from MeOH afforded 10
–1
(0.4 g, 57%), mp 125–128°C. IR spectrum (ꢃ, cm ): 1710 (C=O), 1640 (C=C). PMR spectrum (ꢁ, ppm): 0.67 (3H, s,
18-CH ), 0.85 (3H, s, 19-CH ), 2.05 (3H, s, 21-CH ), 5.52 (2H, complicated m, H-2, H-3).
3
3
3
20-Hydroximino-5ꢀ-pregn-2-ene (7). A mixture of 10 (0.4 g, 1.3 mmol) and NH OH4HCl (0.1 g, 1.47 mmol) in Py
2
(5 mL) was heated at 65–70°C for 3 h, cooled to 20°C, and poured into icewater (50 mL). The precipitate was filtered off,
–1
washed with water, and dried to afford 7 (0.38 g, 90%), mp 113–115°C (MeOH). IR spectrum (ꢃ, cm ): 1680 (C=N), 1640
(C=C). PMR spectrum (ꢁ, ppm): 0.61 (3H, s, 18-CH ), 0.74 (3H, s, 19-CH ), 1.86 (3H, s, 21-CH ), 5.56 (2H, complicated m,
3
3
3
H-2, H-3), 8.28 (br.s, CN–OH).
ACKNOWLEDGMENT
The work was supported financially by the Georgian National Science Foundation (Grant No. GNSF/ST08/4-406).
We thank Dr. K. Lange for performing the biological experiments.
REFERENCES
1.
N. M. Krstic, M. S. Bjelakovic, Z. Zizar, M. D. Pavlovic, Z. D. Juranic, and V. D. Pavlovich, Steroids, 72, 406
(2007).
2.
3.
J. Cui, L. Huang, L. Fan, and A. Zhou, Steroids, 73, 252 (2008).
N. Sh. Nadaraia, V. I. Sladkov, E. V. Dorodnikova, M. D. Mashkovskii, E. P. Kemertelidze, and N. N. Suvorov,
Khim.-farm. Zh., 22, 3, 288 (1988).
4.
5.
6.
7.
M. Sikharulidze, M. Davitashvili, and L. Kintsurashvili, Bull. Georgian Acad. Sci., 159, 2, 286 (1999).
N. Sh. Nadaraia, V. I. Sladkov, L. N. Kuleshova, and N. N. Suvorov, Zh. Org. Khim., 23, 3, 533 (1987).
O. S. Madaeva, Zh. Org. Khim., 27, 9, 2573 (1957).
S. Takatsuto and N. Ikekawa, Chem. Pharm. Bull., 35, 3, 986 (1987).
494